Review



akt sirna  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology akt sirna
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 97 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 97 article reviews
    akt sirna - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Daunorubicin induces GLI1-dependent apoptosis in colorectal cancer cell lines"

    Article Title: Daunorubicin induces GLI1-dependent apoptosis in colorectal cancer cell lines

    Journal: International Journal of Oncology

    doi: 10.3892/ijo.2024.5654

    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 siRNA, cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Figure Legend Snippet: Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 siRNA, cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.

    Techniques Used: Colony Assay, Quantitation Assay, Activity Assay, Western Blot, Expressing, Knockdown, Small Interfering RNA

    Daunorubicin induces p53-mediated apoptosis and GLI1 downregulation in HCT116 cells. (A) After AKT or ERK knockdown using siRNA, cell survival induced by daunorubicin was detected. (B) A phospho-kinase antibody array analysis showed that daunorubicin substantially increased p53 phosphorylation (S15, S46 and S392). The quantitation is depicted in the lower panel. (C) Western blot analysis for apoptosis-related marker proteins following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (D) Western blotting was used to measure the expression levels of c-PARP, p53, GLI1, p21 and Cyclin D1 in HCT116 and HCT116 p53 knockout cells. (E) Western blot analysis for PCAF and p300 following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (F) Results of daunorubicin (0.5 and 1 μ M) treatment for 24 h after PCAF knockdown using PCAF siRNA. The data are expressed as the mean of 3 independent experiments. siRNA, small interfering RNA; K/O, knockout; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Figure Legend Snippet: Daunorubicin induces p53-mediated apoptosis and GLI1 downregulation in HCT116 cells. (A) After AKT or ERK knockdown using siRNA, cell survival induced by daunorubicin was detected. (B) A phospho-kinase antibody array analysis showed that daunorubicin substantially increased p53 phosphorylation (S15, S46 and S392). The quantitation is depicted in the lower panel. (C) Western blot analysis for apoptosis-related marker proteins following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (D) Western blotting was used to measure the expression levels of c-PARP, p53, GLI1, p21 and Cyclin D1 in HCT116 and HCT116 p53 knockout cells. (E) Western blot analysis for PCAF and p300 following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (F) Results of daunorubicin (0.5 and 1 μ M) treatment for 24 h after PCAF knockdown using PCAF siRNA. The data are expressed as the mean of 3 independent experiments. siRNA, small interfering RNA; K/O, knockout; c-PARP, cleaved poly (ADP-ribose) polymerase.

    Techniques Used: Knockdown, Ab Array, Phospho-proteomics, Quantitation Assay, Western Blot, Marker, Expressing, Knock-Out, Small Interfering RNA

    Daunorubicin promotes GLI1 ubiquitination and proteasomal degradation. (A) HCT116 cells were treated with 2 μ M MG132 or 100 μ M leupeptin. (B) CHX chase assay showed that daunorubicin reduced the stability of GLI1 protein. Quantitation of GLI1 is also plotted. (C and D) Daunorubicin promoted the ubiquitination of GLI1 in HCT-116 cells. Immunoprecipitation using antibodies against each of the three E3 ligases revealed a major enhancement of β-TrCP-GLI1 interaction. (E) Results of daunorubicin (1 μ M) treatment for 24 h after β-TrCP knockdown using β-TrCP siRNA. Immunoprecipitation using GLI1 and β-TrCP antibody. The data are expressed as the mean of 3 independent experiments. ** P<0.005 and *** P<0.001. CHX, cycloheximide; siRNA, small interfering RNA.
    Figure Legend Snippet: Daunorubicin promotes GLI1 ubiquitination and proteasomal degradation. (A) HCT116 cells were treated with 2 μ M MG132 or 100 μ M leupeptin. (B) CHX chase assay showed that daunorubicin reduced the stability of GLI1 protein. Quantitation of GLI1 is also plotted. (C and D) Daunorubicin promoted the ubiquitination of GLI1 in HCT-116 cells. Immunoprecipitation using antibodies against each of the three E3 ligases revealed a major enhancement of β-TrCP-GLI1 interaction. (E) Results of daunorubicin (1 μ M) treatment for 24 h after β-TrCP knockdown using β-TrCP siRNA. Immunoprecipitation using GLI1 and β-TrCP antibody. The data are expressed as the mean of 3 independent experiments. ** P<0.005 and *** P<0.001. CHX, cycloheximide; siRNA, small interfering RNA.

    Techniques Used: Ubiquitin Proteomics, Protein Quantitation, Immunoprecipitation, Knockdown, Small Interfering RNA



    Similar Products

    akt sirna  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology akt sirna
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    akt sirna - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    akt1 2 shrna lentiviral particles  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology akt1 2 shrna lentiviral particles
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt1 2 Shrna Lentiviral Particles, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt1 2 shrna lentiviral particles/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    akt1 2 shrna lentiviral particles - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    akt1 2 sirna  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology akt1 2 sirna
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt1 2 Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt1 2 sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    akt1 2 sirna - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    akt1 2  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc akt1 2
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt1 2/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    akt1 2 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    akt1 2  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology akt1 2
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt1 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt1 2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    akt1 2 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    4e bp1  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology 4e bp1
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    4e Bp1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/4e bp1/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    4e bp1 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    akt1 2sirna m santa cruz biotechnology  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology akt1 2sirna m santa cruz biotechnology
    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 <t>siRNA,</t> cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.
    Akt1 2sirna M Santa Cruz Biotechnology, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt1 2sirna m santa cruz biotechnology/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    akt1 2sirna m santa cruz biotechnology - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 siRNA, cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.

    Journal: International Journal of Oncology

    Article Title: Daunorubicin induces GLI1-dependent apoptosis in colorectal cancer cell lines

    doi: 10.3892/ijo.2024.5654

    Figure Lengend Snippet: Daunorubicin-induced caspase-dependent apoptosis in HCT116 cells. (A) Daunorubicin decreased the proliferation of HCT116, HT29, SNU283, DLD-1 and HCT8 cells with GI 50 of 0.597, 0.547, 0.6934, 25.55 and 34.93 μ M, respectively. (B) Colony formation assay using HCT116 cells after treatment of daunorubicin (0, 0.5 and 1) and quantitation. (C) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h-induced apoptosis of HCT116 cells in a dose-dependent manner. Quantitation of cell death is plotted on the right. The graph was drawn by combining the B2 and B4 quadrants. (D) Treatment of daunorubicin (0, 0.5 and 1 μ M) for 24 h led to a dose-dependent increase in caspase3/7 activity. (E) HCT116 cells were pretreated with 25 μ M z-VAD-fmk for 30 min and then treated with daunorubicin (0, 0.5 and 1 μ M). Western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. (F) After GLI1 knockdown using GLI1 siRNA, cell survival induced by daunorubicin was detected. (G) After GLI1 knockdown using GLI1 siRNA, western blotting was used to measure the expression levels of c-PARP, caspase3, caspase9 and caspase8. The data are expressed as the mean of 3 independent experiments. **P<0.005, *** P<0.001 and **** P<0.0001. siRNA, small interfering RNA; c-PARP, cleaved poly (ADP-ribose) polymerase.

    Article Snippet: Con siRNA (cat. no. sc-37007), GLI1 siRNA (cat. no. sc-37911), AKT siRNA (cat. no. sc-43609), ERK siRNA (cat. no. sc-29307, sc-35335), PCAF siRNA (cat. no. sc-36198) and β-TrCP siRNA (cat. no. sc-37178) were all purchased from Santa Cruz Biotechnology, Inc (The siRNA sequence is unavailable by Santa Cruz Biotechnology, Inc).

    Techniques: Colony Assay, Quantitation Assay, Activity Assay, Western Blot, Expressing, Knockdown, Small Interfering RNA

    Daunorubicin induces p53-mediated apoptosis and GLI1 downregulation in HCT116 cells. (A) After AKT or ERK knockdown using siRNA, cell survival induced by daunorubicin was detected. (B) A phospho-kinase antibody array analysis showed that daunorubicin substantially increased p53 phosphorylation (S15, S46 and S392). The quantitation is depicted in the lower panel. (C) Western blot analysis for apoptosis-related marker proteins following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (D) Western blotting was used to measure the expression levels of c-PARP, p53, GLI1, p21 and Cyclin D1 in HCT116 and HCT116 p53 knockout cells. (E) Western blot analysis for PCAF and p300 following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (F) Results of daunorubicin (0.5 and 1 μ M) treatment for 24 h after PCAF knockdown using PCAF siRNA. The data are expressed as the mean of 3 independent experiments. siRNA, small interfering RNA; K/O, knockout; c-PARP, cleaved poly (ADP-ribose) polymerase.

    Journal: International Journal of Oncology

    Article Title: Daunorubicin induces GLI1-dependent apoptosis in colorectal cancer cell lines

    doi: 10.3892/ijo.2024.5654

    Figure Lengend Snippet: Daunorubicin induces p53-mediated apoptosis and GLI1 downregulation in HCT116 cells. (A) After AKT or ERK knockdown using siRNA, cell survival induced by daunorubicin was detected. (B) A phospho-kinase antibody array analysis showed that daunorubicin substantially increased p53 phosphorylation (S15, S46 and S392). The quantitation is depicted in the lower panel. (C) Western blot analysis for apoptosis-related marker proteins following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (D) Western blotting was used to measure the expression levels of c-PARP, p53, GLI1, p21 and Cyclin D1 in HCT116 and HCT116 p53 knockout cells. (E) Western blot analysis for PCAF and p300 following treatment of daunorubicin (0.5 and 1 μ M) for 24 h. (F) Results of daunorubicin (0.5 and 1 μ M) treatment for 24 h after PCAF knockdown using PCAF siRNA. The data are expressed as the mean of 3 independent experiments. siRNA, small interfering RNA; K/O, knockout; c-PARP, cleaved poly (ADP-ribose) polymerase.

    Article Snippet: Con siRNA (cat. no. sc-37007), GLI1 siRNA (cat. no. sc-37911), AKT siRNA (cat. no. sc-43609), ERK siRNA (cat. no. sc-29307, sc-35335), PCAF siRNA (cat. no. sc-36198) and β-TrCP siRNA (cat. no. sc-37178) were all purchased from Santa Cruz Biotechnology, Inc (The siRNA sequence is unavailable by Santa Cruz Biotechnology, Inc).

    Techniques: Knockdown, Ab Array, Phospho-proteomics, Quantitation Assay, Western Blot, Marker, Expressing, Knock-Out, Small Interfering RNA

    Daunorubicin promotes GLI1 ubiquitination and proteasomal degradation. (A) HCT116 cells were treated with 2 μ M MG132 or 100 μ M leupeptin. (B) CHX chase assay showed that daunorubicin reduced the stability of GLI1 protein. Quantitation of GLI1 is also plotted. (C and D) Daunorubicin promoted the ubiquitination of GLI1 in HCT-116 cells. Immunoprecipitation using antibodies against each of the three E3 ligases revealed a major enhancement of β-TrCP-GLI1 interaction. (E) Results of daunorubicin (1 μ M) treatment for 24 h after β-TrCP knockdown using β-TrCP siRNA. Immunoprecipitation using GLI1 and β-TrCP antibody. The data are expressed as the mean of 3 independent experiments. ** P<0.005 and *** P<0.001. CHX, cycloheximide; siRNA, small interfering RNA.

    Journal: International Journal of Oncology

    Article Title: Daunorubicin induces GLI1-dependent apoptosis in colorectal cancer cell lines

    doi: 10.3892/ijo.2024.5654

    Figure Lengend Snippet: Daunorubicin promotes GLI1 ubiquitination and proteasomal degradation. (A) HCT116 cells were treated with 2 μ M MG132 or 100 μ M leupeptin. (B) CHX chase assay showed that daunorubicin reduced the stability of GLI1 protein. Quantitation of GLI1 is also plotted. (C and D) Daunorubicin promoted the ubiquitination of GLI1 in HCT-116 cells. Immunoprecipitation using antibodies against each of the three E3 ligases revealed a major enhancement of β-TrCP-GLI1 interaction. (E) Results of daunorubicin (1 μ M) treatment for 24 h after β-TrCP knockdown using β-TrCP siRNA. Immunoprecipitation using GLI1 and β-TrCP antibody. The data are expressed as the mean of 3 independent experiments. ** P<0.005 and *** P<0.001. CHX, cycloheximide; siRNA, small interfering RNA.

    Article Snippet: Con siRNA (cat. no. sc-37007), GLI1 siRNA (cat. no. sc-37911), AKT siRNA (cat. no. sc-43609), ERK siRNA (cat. no. sc-29307, sc-35335), PCAF siRNA (cat. no. sc-36198) and β-TrCP siRNA (cat. no. sc-37178) were all purchased from Santa Cruz Biotechnology, Inc (The siRNA sequence is unavailable by Santa Cruz Biotechnology, Inc).

    Techniques: Ubiquitin Proteomics, Protein Quantitation, Immunoprecipitation, Knockdown, Small Interfering RNA